MA30202B1 - Composes organiques - Google Patents
Composes organiquesInfo
- Publication number
- MA30202B1 MA30202B1 MA30987A MA30987A MA30202B1 MA 30202 B1 MA30202 B1 MA 30202B1 MA 30987 A MA30987 A MA 30987A MA 30987 A MA30987 A MA 30987A MA 30202 B1 MA30202 B1 MA 30202B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- diseases
- formula
- treatment
- insulin resistance
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 102000014400 SH2 domains Human genes 0.000 abstract 1
- 108050003452 SH2 domains Proteins 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 206010024627 liposarcoma Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Les composés de formule sont des inhibiteurs des protéines tyrosines phosphatases (PTPases) et, ainsi, peuvent être employés pour le traitement de maladies provoquées par l'intermédiaire de l'activité de la PTPase. Les composés de la présente invention peuvent également être employés en tant qu'inhibiteurs d'autres enzymes caractérisés par une région de liaison à la phosphotyrosine tel que le domaine SH2. De même, les composés de formule (I) peuvent être employés pour la prévention et/ou le traitement de la résistance à l'insuline associée à l'obésité, de l'intolérance au glucose, du diabète sucré, de l'hypertension et des maladies ischémiques des grands et des petits vaisseaux sanguins, des maladies qui accompagnent le diabète de type 2, y compris l'hyperlipidémie, l'hypertriglycéridémie, l'athérosclérose, la resténose vasculaire, le syndrome du côlon irritable, la pancréatite, les tumeurs et carcinomes cellulaires adipeux tels que le liposarcome, la dyslipidémie et les autres troubles au cours desquels une résistance à l'insuline est indiquée. De plus, les composés de la présente invention peuvent être employés pour traiter et/ou prévenir le cancer (tel que le cancer de la prostate ou du sein), l'ostéoporose, les maladies neurodégénératives et infectieuses, et les maladies impliquant une inflammation ainsi que le système immunitaire.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74857305P | 2005-12-08 | 2005-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30202B1 true MA30202B1 (fr) | 2009-02-02 |
Family
ID=37950917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30987A MA30202B1 (fr) | 2005-12-08 | 2008-06-02 | Composes organiques |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7700633B2 (fr) |
| EP (1) | EP1963292B1 (fr) |
| JP (1) | JP2009519248A (fr) |
| KR (1) | KR20080074969A (fr) |
| CN (1) | CN101326173A (fr) |
| AR (1) | AR056838A1 (fr) |
| AT (1) | ATE546440T1 (fr) |
| AU (1) | AU2006321905B2 (fr) |
| BR (1) | BRPI0619600A2 (fr) |
| CA (1) | CA2629857A1 (fr) |
| CR (1) | CR10049A (fr) |
| EC (1) | ECSP088506A (fr) |
| ES (1) | ES2381280T3 (fr) |
| IL (1) | IL191549A0 (fr) |
| MA (1) | MA30202B1 (fr) |
| NO (1) | NO20083031L (fr) |
| NZ (1) | NZ568243A (fr) |
| PE (2) | PE20071031A1 (fr) |
| PL (1) | PL1963292T3 (fr) |
| PT (1) | PT1963292E (fr) |
| RU (1) | RU2008127254A (fr) |
| TN (1) | TNSN08249A1 (fr) |
| TW (1) | TW200732315A (fr) |
| UA (1) | UA94724C2 (fr) |
| WO (1) | WO2007067615A2 (fr) |
| ZA (1) | ZA200804074B (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2630448A1 (fr) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1, 1, 3-tri0x0-1, 2, 5-thiadiaz0lidines et leur utilisation comme inhibiteurs des ptp-ases |
| UA94921C2 (en) | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| CA2629819A1 (fr) * | 2005-12-08 | 2007-06-14 | Novartis Ag | Derives de 1,2,5-thiazolidine utiles dans le traitement d'etats induits par les proteine tyrosine phosphatases (ptpase) |
| WO2008067527A1 (fr) * | 2006-12-01 | 2008-06-05 | Novartis Ag | Inhibiteurs de la protéine tyrosine phosphatase pour le traitement d'une atrophie musculaire et de troubles associés |
| AR066820A1 (es) * | 2007-06-04 | 2009-09-16 | Novartis Ag | Compuestos de tiadiazolidin-3 ona |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| CN110536685A (zh) | 2016-12-23 | 2019-12-03 | 昆士兰大学 | Sox18蛋白活性的抑制剂用于治疗血管生成相关疾病和/或淋巴管生成相关疾病 |
| BR112020026086A2 (pt) * | 2018-06-21 | 2021-03-23 | Calico Life Sciences Llc | inibidores da proteína tirosina fosfatase e métodos de uso destes |
| BR112021012311A2 (pt) | 2018-12-21 | 2021-09-08 | Crystal Pharma, S.A.U. | Uso de um composto intermediário, processo para preparar voxelotor e composto intermediário |
| IL286373B2 (en) * | 2019-03-14 | 2026-03-01 | Calico Life Sciences Llc | Protein tyrosine phosphate inhibitor compounds and uses thereof |
| GB201915094D0 (en) * | 2019-10-18 | 2019-12-04 | Balticgruppen Bio Ab | New formulations |
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| EP4073242A4 (fr) | 2019-12-12 | 2024-01-03 | Kumquat Biosciences Inc. | Compositions et procédés pour potentialiser l'activité immunitaire |
| EP4077319A1 (fr) * | 2019-12-20 | 2022-10-26 | Calico Life Sciences LLC | Agents de dégradation de protéine tyrosine phosphatase et leurs méthodes d'utilisation |
| WO2022192598A1 (fr) * | 2021-03-11 | 2022-09-15 | Kumquat Biosciences Inc. | Hétérocycles et leurs utilisations |
| EP4359409A1 (fr) * | 2021-06-21 | 2024-05-01 | Calico Life Sciences LLC | Composés de dégradation et leurs utilisations |
| WO2023086498A1 (fr) * | 2021-11-11 | 2023-05-19 | Calico Life Sciences Llc | Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation |
| WO2023150150A1 (fr) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
| WO2023150535A1 (fr) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
| PE20250780A1 (es) * | 2022-02-02 | 2025-03-14 | Nerio Therapeutics Inc | Inhibidores de proteina tirosina fosfatasa y usos de estos |
| CN119790052A (zh) * | 2022-09-13 | 2025-04-08 | 金橘生物科技公司 | 苯并稠合的n-杂环及其用途 |
| WO2024067802A1 (fr) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | Inhibiteur de protéine tyrosine phosphatase, son procédé de préparation et son utilisation pharmaceutique |
| WO2024141015A1 (fr) * | 2022-12-30 | 2024-07-04 | Insilico Medicine Ip Limited | Inhibiteurs de protéine tyrosine phosphatase et leurs utilisations |
| CN118852335A (zh) * | 2023-04-28 | 2024-10-29 | 中科中山药物创新研究院 | 噻二唑烷酮衍生物及其制备方法和应用 |
| CN116496248B (zh) * | 2023-05-06 | 2025-09-02 | 江苏艾科姆检测有限公司 | 一种溴氰虫酰胺杂质的合成方法 |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| AU2024288616A1 (en) * | 2023-07-11 | 2026-02-12 | Shenzhen Zhongge Biological Technology Co., Ltd. | Protein tyrosine phosphatase inhibitor, composition comprising same, and medical use thereof |
| CN120004876B (zh) * | 2023-11-16 | 2026-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
| WO2025242216A1 (fr) * | 2024-05-24 | 2025-11-27 | 杭州百新生物医药科技有限公司 | Composés indolines et leur utilisation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100868587B1 (ko) * | 2002-04-03 | 2008-11-12 | 노파르티스 아게 | Ｐｔｐａｓｅ 1ｂ 억제제로서의 5-치환된1,1-디옥소-1,2,5-티아졸리딘-3-온 유도체 |
| GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
| EP1594497B1 (fr) * | 2002-12-30 | 2009-05-27 | Vertex Pharmaceuticals Incorporated | Sulfhydantoines utilisees comme isosteres phosphate |
| US7141596B2 (en) * | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
| CA2630448A1 (fr) * | 2005-12-08 | 2007-06-14 | Novartis Ag | 1, 1, 3-tri0x0-1, 2, 5-thiadiaz0lidines et leur utilisation comme inhibiteurs des ptp-ases |
| CA2629819A1 (fr) * | 2005-12-08 | 2007-06-14 | Novartis Ag | Derives de 1,2,5-thiazolidine utiles dans le traitement d'etats induits par les proteine tyrosine phosphatases (ptpase) |
| CA2647472A1 (fr) * | 2006-03-31 | 2007-10-11 | Novartis Ag | Composes organiques |
-
2006
- 2006-06-12 UA UAA200807751A patent/UA94724C2/ru unknown
- 2006-12-06 WO PCT/US2006/046545 patent/WO2007067615A2/fr not_active Ceased
- 2006-12-06 JP JP2008544467A patent/JP2009519248A/ja active Pending
- 2006-12-06 BR BRPI0619600-4A patent/BRPI0619600A2/pt not_active IP Right Cessation
- 2006-12-06 AT AT06839094T patent/ATE546440T1/de active
- 2006-12-06 CA CA002629857A patent/CA2629857A1/fr not_active Abandoned
- 2006-12-06 PL PL06839094T patent/PL1963292T3/pl unknown
- 2006-12-06 AR ARP060105392A patent/AR056838A1/es not_active Application Discontinuation
- 2006-12-06 PT PT06839094T patent/PT1963292E/pt unknown
- 2006-12-06 AU AU2006321905A patent/AU2006321905B2/en not_active Ceased
- 2006-12-06 CN CNA2006800461637A patent/CN101326173A/zh active Pending
- 2006-12-06 ES ES06839094T patent/ES2381280T3/es active Active
- 2006-12-06 PE PE2006001571A patent/PE20071031A1/es not_active Application Discontinuation
- 2006-12-06 PE PE2010000531A patent/PE20100733A1/es not_active Application Discontinuation
- 2006-12-06 EP EP06839094A patent/EP1963292B1/fr active Active
- 2006-12-06 NZ NZ568243A patent/NZ568243A/en not_active IP Right Cessation
- 2006-12-06 KR KR1020087013716A patent/KR20080074969A/ko not_active Ceased
- 2006-12-06 US US12/096,439 patent/US7700633B2/en not_active Expired - Fee Related
- 2006-12-06 RU RU2008127254/04A patent/RU2008127254A/ru not_active Application Discontinuation
- 2006-12-07 TW TW095145713A patent/TW200732315A/zh unknown
-
2008
- 2008-05-13 ZA ZA200804074A patent/ZA200804074B/xx unknown
- 2008-05-19 IL IL191549A patent/IL191549A0/en unknown
- 2008-06-02 MA MA30987A patent/MA30202B1/fr unknown
- 2008-06-05 CR CR10049A patent/CR10049A/es not_active Application Discontinuation
- 2008-06-06 EC EC2008008506A patent/ECSP088506A/es unknown
- 2008-06-06 TN TNP2008000249A patent/TNSN08249A1/en unknown
- 2008-07-04 NO NO20083031A patent/NO20083031L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20071031A1 (es) | 2007-11-15 |
| ECSP088506A (es) | 2008-07-30 |
| EP1963292A2 (fr) | 2008-09-03 |
| TW200732315A (en) | 2007-09-01 |
| US7700633B2 (en) | 2010-04-20 |
| ZA200804074B (en) | 2009-03-25 |
| PE20100733A1 (es) | 2010-10-29 |
| NZ568243A (en) | 2011-07-29 |
| NO20083031L (no) | 2008-08-28 |
| PT1963292E (pt) | 2012-05-10 |
| ATE546440T1 (de) | 2012-03-15 |
| JP2009519248A (ja) | 2009-05-14 |
| ES2381280T3 (es) | 2012-05-24 |
| EP1963292B1 (fr) | 2012-02-22 |
| CR10049A (es) | 2008-08-25 |
| US20080262050A1 (en) | 2008-10-23 |
| PL1963292T3 (pl) | 2012-07-31 |
| KR20080074969A (ko) | 2008-08-13 |
| WO2007067615A2 (fr) | 2007-06-14 |
| IL191549A0 (en) | 2008-12-29 |
| BRPI0619600A2 (pt) | 2011-10-11 |
| WO2007067615A3 (fr) | 2007-11-15 |
| TNSN08249A1 (en) | 2009-10-30 |
| AU2006321905A1 (en) | 2007-06-14 |
| AU2006321905B2 (en) | 2011-08-11 |
| CA2629857A1 (fr) | 2007-06-14 |
| RU2008127254A (ru) | 2010-01-20 |
| UA94724C2 (en) | 2011-06-10 |
| AR056838A1 (es) | 2007-10-24 |
| CN101326173A (zh) | 2008-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30202B1 (fr) | Composes organiques | |
| MA30018B1 (fr) | Derives de 1-orthofluorophenyl substitues 1, 2, 5-thiazolidinedione utilises comme inhibiteurs de la ptp-ase | |
| Lu et al. | Structure and functions of angiotensinogen | |
| Fleming et al. | The tissue renin–angiotensin system and intracellular signalling | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| EP1888066A4 (fr) | Aminocyclohexanes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
| EP1796669A4 (fr) | Aminopiperidines utilisees comme inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
| Arnett et al. | Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study | |
| Seno et al. | Pyrrolidine inhibitors of human cytosolic phospholipase A2 | |
| EP1624874A4 (fr) | Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete | |
| EP1921917A4 (fr) | Aminopiperidines fusionnees utilisees comme inhibiteurs de dipeptidyl-peptidase-iv pour le traitement ou la prevention du diabete | |
| MA33606B1 (fr) | Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2 | |
| Lazaar et al. | Mast cell chymase modifies cell-matrix interactions and inhibits mitogen-induced proliferation of human airway smooth muscle cells | |
| MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
| EP1841770A4 (fr) | Pyrimidines bicycliques en tant qu'inhibiteurs de la dipeptidyl-peptidase-iv dans le traitement ou la prevention de diabetes | |
| MA31862B1 (fr) | Anticorps anti-mésothéline et leurs utilisations | |
| MA35874B1 (fr) | Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci | |
| MA32887B1 (fr) | Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete | |
| EP1635818A4 (fr) | Indoles fusionnes en tant qu'inhibiteurs de dipeptidyle peptidase destines au traitement ou a la prevention des diabetes | |
| BR0308974A (pt) | Derivados de 1,1-dioxo-1,2,5-tiazolidina-3-ona 5-substituìdos como inibidores de ptpase 1b | |
| MA29444B1 (fr) | Antagonistes npy, preparation et utilisations | |
| MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
| EP1490335A4 (fr) | Inhibiteurs de la dipeptidyl peptidase beta-amino heterocycliques pour le traitement ou la prevention du diabete | |
| MA30975B1 (fr) | Formulation parenterale d'anticorps anti-peptide abeta | |
| EP1819674A4 (fr) | Aminopiperidines fusionnees utilisees comme inhibiteurs de la dipeptidyle peptidase-iv permettant de traiter ou de prevenir le diabete |